KR100769786B1 - 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 - Google Patents
메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 Download PDFInfo
- Publication number
- KR100769786B1 KR100769786B1 KR1020027005673A KR20027005673A KR100769786B1 KR 100769786 B1 KR100769786 B1 KR 100769786B1 KR 1020027005673 A KR1020027005673 A KR 1020027005673A KR 20027005673 A KR20027005673 A KR 20027005673A KR 100769786 B1 KR100769786 B1 KR 100769786B1
- Authority
- KR
- South Korea
- Prior art keywords
- glyburide
- metformin
- dose
- less
- complex
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
제품 | 성분의 양, mg/정제 250/1.25 또는 500/2.5 또는 500/5.0 |
성분 | |
메트포르민 염산염 | 250.0 또는 500.0 |
글리부라이드 | 1.25 또는 2.5 또는 5 |
크로스카르멜로즈 소듐 | 3.0-15.0 |
미세결정성 셀룰로우즈 | 15.0-60.0 |
폴리비닐피롤리돈 | 3.0-20 |
마그네슘 스테아레이트 | 0.3-7.5 |
필름 코트* | 4.5-12.0 |
*오파드라이(Opadry: 콜로르콘(Colorcon), 영국)과 같이 상업적으로 구입이 가능한 필름 코트 조성물이 사용됨. |
제품 | 성분의 양, mg/정제 250/1.25 500/2.5 500/5.0 |
성분 | |
메트포르민 염산염* | 251.25 502.50 502.50 |
글리부라이드 | 1.25 2.5 5.0 |
크로스카르멜로즈 소듐 | 7.0 14 14 |
미세결정성 셀룰로우즈 | 28.25 56.50 54.0 |
폴리비닐피롤리돈 | 10.0 20 20 |
마그네슘 스테아레이트 | 2.25 4.50 4.50 |
필름 코트** | 6 12.0 12.0 |
* 99.5%(w/w) 메트포르민 염산염 및 0.5%(w/w) 마그네슘 스테아레이트를 포함한다. ** 오파드라이(Opadry: 콜로르콘(Colorcon), 영국)과 같이 상업적으로 구입이 가능한 필름 코트 조성물이 사용됨. |
실시예 1 실시예 2 실시예 3 | |||
성분 | 정제 당 양(mg) 250mg/1.25mg 500mg/2.5mg 500mg/5.0mg | ||
메트포르민 염산염* | 251.25 | 502.50 | 502.50 |
글리부라이드 | 1.25 | 2.5 | 5 |
크로스카르멜로즈 소듐 | 7.00 | 14.0 | 14.0 |
포비돈 | 10.00 | 20.0 | 20.0 |
미세결정성 셀룰로우즈 | 28.25 | 56.5 | 54.0 |
마그네슘 스테아레이트 | 2.25 | 4.5 | 4.5 |
필름 코트** | 6 | 12 | 12 |
* 99.5%(w/w) 메트포르민 염산염 및 0.5%(w/w) 마그네슘 스테아레이트를 포함한다. **HPMC계 필름 코트 사용 |
배치 번호 | 입자크기A (단위는 동등한 구 지름 (㎛)임) | ||
25% 미만크기 | 50% 미만크기 | 75% 미만크기 | |
1 | 5 | 9 | 21 |
2 | 5 | 9 | 21 |
3 | 4 | 8 | 18 |
4 | 5 | 9 | 18 |
A입자크기는 레이저광산란으로 측정하였다. 참고방법 #CRM 8532(#SM 248533) |
Claims (43)
- 메트포르민 250 mg 및 글리부라이드 1.25 mg을 함유하는, 저용량의 메트포르민 및 글리부라이드 복합물을 포함하며, 상기 글리부라이드가 글리부라이드 입자 중 10% 이하가 2㎛ 미만이며, 글리부라이드 입자 중 10% 이하가 60㎛ 초과인 입자 크기 분포를 가지며, 상기 저용량 복합물 중의 메트포르민이 160 mg 내지 750 mg 범위 내의 1일 용량으로 투여되고, 상기 저용량 복합물 중의 글리부라이드가 0.5 mg 내지 15 mg 범위 내의 1일 용량으로 투여되는 것인, 투약 경험이 없는 사람환자의 타입 2 당뇨병의 1차 치료용 제약 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 메트포르민 및 글리부라이드의 저용량 복합물이 단일 투여 형태로 제제화된 제약 조성물.
- 삭제
- 삭제
- 제1항에 있어서, 상기 저용량 복합물 중의 메트포르민이 160 내지 750 mg 범위 내의 양으로 1일 1 내지 4회 투여되고, 메트포르민의 1일 용량이 225 mg보다 많지만 최대 750 mg이며, 상기 저용량 복합물 중의 글리부라이드가 1일 최대 15 mg까지 0.75 내지 5 mg 범위의 양으로 1일 1 내지 4회 투여되는 것인 제약 조성물.
- 제1항에 있어서, 상기 저용량 복합물 중의 메트포르민이 250 내지 500 mg 범위 내의 양으로 투여되고, 상기 저용량 복합물 중의 글리부라이드가 1.25 내지 5 mg 범위의 양으로 투여되는 것인 제약 조성물.
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 상기 저용량 복합물 중의 메트포르민/글리부라이드 복합물이 1일 1회 또는 2회 투여되는 250 mg 메트포르민/1.25 mg 글리부라이드를 포함하는 것인 제약 조성물.
- 제17항에 있어서, 250 mg 메트포르민/1.25 mg 글리부라이드를 기준선 헤모글로빈 A1c (HbA1c) > 9% 또는 공복 혈당 > 200 mg/dL인 환자에게 1일 2회 투여하고, 필요한 경우 용량을 2주마다 250 mg 메트포르민/1.25 mg 글리부라이드 씩 증가시켜 적절한 혈당조절에 필요한 최소 유효 1일 용량까지 높이는 제약 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 메트포르민 250 mg 및 글리부라이드 1.25 mg을 함유하는, 치료적으로 유효한 저용량의 메트포르민 및 글리부라이드의 복합물을 포함하며, 상기 글리부라이드가 글리부라이드 입자 중 10% 이하가 2㎛ 미만이며, 글리부라이드 입자 중 10% 이하가 60㎛ 초과인 입자 크기 분포를 가지고, 상기 저용량 복합물 중의 메트포르민이 160 mg 내지 750 mg 범위 내의 1일 용량으로 투여되고, 상기 저용량 복합물 중의 글리부라이드가 0.5 mg 내지 15 mg 범위 내의 1일 용량으로 투여되는 것인, 상기 글리부라이드 생체 이용률이 메트포르민 및 글리부라이드의 개별 투여로부터 얻어진 글리부라이드 생체이용률과 동등한 것인, 투약경험이 없는 사람환자의 타입 2 당뇨병의 1차 치료용 제약 조성물.
- 삭제
- 제25항에 있어서, 상기 글리부라이드 입자 중 10% 이하가 3㎛ 미만이고, 글리부라이드 입자 중 10% 이하가 40㎛ 초과인 제약 조성물.
- 제25항에 있어서, 상기 글리부라이드 입자 중 25% 이하가 11㎛ 미만이고, 글리부라이드 입자 중 25% 이하가 46㎛ 초과인 제약 조성물.
- 제25항에 있어서, 상기 글리부라이드 입자 중 50%가 23㎛ 미만인 제약 조성물.
- 제25항에 있어서, 상기 글리부라이드가 25% 미만의 크기 값이 6 ㎛ 이하, 50% 미만의 크기값이 7 내지 10 ㎛, 75% 미만의 크기값이 23 ㎛ 이하인 입자 크기 분포를 갖는 제약 조성물.
- 제25항에 있어서, 시작 1일 용량이 250 mg 메트포르민/1.25 mg 글리부라이드 또는 500 mg 메트포르민/2.5 mg 글리부라이드인 제약 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 메트포르민 250 mg 및 글리부라이드 1.25 mg을 함유하는, 저용량의 메트포르민 및 글리부라이드 복합물을 포함하며, 시작 1일 용량이 250 mg 메트포르민 및 1.25 mg 글리부라이드이고, 상기 글리부라이드가 글리부라이드 입자 중 10% 이하가 2㎛ 미만이며, 글리부라이드 입자 중 10% 이하가 60㎛ 초과인 입자 크기 분포를 가지는, 투약경험이 없는 사람환자의 타입 2 당뇨병의 1차 치료용 제약 조성물.
- 메트포르민 250 mg 및 글리부라이드 1.25 mg을 함유하는, 치료적으로 유효한 저용량의 메트포르민 및 글리부라이드 복합물을 포함하며, 상기 글리부라이드가 글리부라이드 입자 중 10% 이하가 2㎛ 미만이며, 글리부라이드 입자 중 10% 이하가 60㎛ 초과인 입자 크기 분포를 가지며, 시작 1일 용량이 하루 2회 250 mg 메트포르민 및 1.25 mg 글리부라이드 또는 하루 1회 500 mg 메트포르민 및 2.5 mg 글리부라이드인, 투약경험이 없는 사람환자의 타입 2 당뇨병의 1차 치료용 제약 조성물.
- 메트포르민 250 mg 및 글리부라이드 1.25 mg을 함유하는, 치료적으로 유효한 저용량의 메트포르민 및 글리부라이드 복합물을 포함하며, 상기 글리부라이드가 글리부라이드 입자 중 10% 이하가 2㎛ 미만이며, 글리부라이드 입자 중 10% 이하가 60㎛ 초과인 입자 크기 분포를 가지며, 시작 1일 용량이 500 mg 메트포르민 및 5 mg 글리부라이드인, 투약경험이 없는 사람환자의 타입 2 당뇨병의 1차 치료용 제약 조성물.
- 메트포르민 250 mg 및 글리부라이드 1.25 mg을 함유하는, 치료적으로 유효한 저용량의 메트포르민 및 글리부라이드 복합물을 포함하며, 상기 글리부라이드가 글리부라이드 입자 중 10% 이하가 2㎛ 미만이며, 글리부라이드 입자 중 10% 이하가 60㎛ 초과인 입자 크기 분포를 가지며, 상기 저용량 복합물 중의 메트포르민이 160 mg 내지 750 mg 범위 내의 1일 용량으로 투여되고, 상기 저용량 복합물 중의 글리부라이드가 0.5 mg 내지 15 mg 범위 내의 1일 용량으로 투여되는 것인, 투약경험이 없는 사람환자의 타입 2 당뇨병의 1차 치료용 제약 조성물.
- 삭제
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/432,465 | 1999-11-03 | ||
US09/432,465 US6586438B2 (en) | 1999-11-03 | 1999-11-03 | Antidiabetic formulation and method |
US09/460,920 | 1999-12-14 | ||
US09/460,920 US7598262B2 (en) | 1999-11-03 | 1999-12-14 | Method for treating diabetes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077018914A Division KR20070089259A (ko) | 1999-11-03 | 2000-10-13 | 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020057994A KR20020057994A (ko) | 2002-07-12 |
KR100769786B1 true KR100769786B1 (ko) | 2007-10-24 |
Family
ID=23716278
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027005673A KR100769786B1 (ko) | 1999-11-03 | 2000-10-13 | 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 |
KR1020027005677A KR20020050253A (ko) | 1999-11-03 | 2000-10-13 | 항당뇨병 제제 및 치료방법 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027005677A KR20020050253A (ko) | 1999-11-03 | 2000-10-13 | 항당뇨병 제제 및 치료방법 |
Country Status (34)
Country | Link |
---|---|
US (2) | US6586438B2 (ko) |
EP (1) | EP1253944A2 (ko) |
JP (2) | JP2003529551A (ko) |
KR (2) | KR100769786B1 (ko) |
CN (3) | CN100386114C (ko) |
AR (1) | AR026355A1 (ko) |
AU (1) | AU781781B2 (ko) |
BG (2) | BG106732A (ko) |
BR (1) | BR0015295A (ko) |
CA (1) | CA2389931A1 (ko) |
CZ (2) | CZ304090B6 (ko) |
DE (1) | DE60038455T2 (ko) |
EE (1) | EE05210B1 (ko) |
ES (1) | ES2302702T3 (ko) |
GE (2) | GEP20053539B (ko) |
HK (1) | HK1045655A1 (ko) |
HU (1) | HUP0300642A3 (ko) |
IL (3) | IL149138A0 (ko) |
LT (1) | LT5025B (ko) |
LV (1) | LV12907B (ko) |
MX (1) | MXPA02004290A (ko) |
MY (2) | MY136636A (ko) |
NO (1) | NO20022086L (ko) |
NZ (1) | NZ552074A (ko) |
PL (1) | PL366112A1 (ko) |
RO (1) | RO123109B1 (ko) |
RU (1) | RU2276604C2 (ko) |
SK (1) | SK4992002A3 (ko) |
TN (2) | TNSN00207A1 (ko) |
TW (1) | TWI241185B (ko) |
UA (2) | UA76706C2 (ko) |
UY (1) | UY26425A1 (ko) |
WO (1) | WO2001032158A2 (ko) |
ZA (2) | ZA200203367B (ko) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US20030040469A1 (en) * | 2000-03-08 | 2003-02-27 | Knudsen Liselotte Bjerre | Lowering serum lipids |
SK14922002A3 (sk) * | 2000-03-17 | 2003-04-01 | Ajinomoto Co., Inc. | Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru |
FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
US7062312B2 (en) * | 2001-01-17 | 2006-06-13 | Pediamed Pharmaceuticals, Inc. | Combination and method including a visual marker for determining compliance with a medication regimen |
US20030022816A1 (en) * | 2001-03-07 | 2003-01-30 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
US20020187926A1 (en) * | 2001-03-07 | 2002-12-12 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
US20040202718A1 (en) * | 2001-09-28 | 2004-10-14 | Tyebji Ziauddin Z. | Dosage form for treatment of diabetes mellitus |
US6924311B2 (en) * | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7183321B2 (en) * | 2001-12-17 | 2007-02-27 | Bristol-Myers Squibb Company | Antidiabetic formulation and method |
MXPA04007183A (es) | 2002-01-25 | 2006-03-06 | Silanes Sa De Cv Lab | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. |
ATE419840T1 (de) | 2002-04-09 | 2009-01-15 | Flamel Tech Sa | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
DK1525219T3 (da) * | 2002-07-04 | 2009-09-07 | Zealand Pharma As | GLP-1 og fremgangsm der til behandling af diabetes |
JP2004067575A (ja) * | 2002-08-06 | 2004-03-04 | Yaizu Suisankagaku Industry Co Ltd | 糖尿病治療薬効果促進剤 |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
SE526943C2 (sv) * | 2002-08-26 | 2005-11-22 | Indevex Ab | Födoämneskompositionsprodukt |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
US20040147564A1 (en) * | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
EP1558220B1 (en) * | 2003-07-24 | 2010-02-10 | Wockhardt Limited | Oral compositions for treatment of diabetes |
JP2007520441A (ja) * | 2003-07-25 | 2007-07-26 | コンジュシェム,インコーポレイティド | 持続性インスリン誘導体及びその方法 |
US20050202063A1 (en) * | 2003-08-26 | 2005-09-15 | Ebn International Kft | Food product |
US20050163837A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone formulations |
US20050163842A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone and metformin formulations |
JP2007535557A (ja) * | 2004-04-29 | 2007-12-06 | アンドルクス ラブス,エルエルシー | 制御放出メトフォルミン組成物 |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
WO2006074278A2 (en) * | 2005-01-05 | 2006-07-13 | Mitsunori Ono | Compositions for treating diabetes or obesity |
JP4974057B2 (ja) * | 2005-01-31 | 2012-07-11 | 味の素株式会社 | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
TW200722088A (en) * | 2005-05-27 | 2007-06-16 | Sankyo Co | Diabetes remedy |
WO2007070355A2 (en) * | 2005-12-09 | 2007-06-21 | Metaproteomics, Llc | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
JP5094416B2 (ja) * | 2005-12-28 | 2012-12-12 | 武田薬品工業株式会社 | 糖尿病治療剤 |
FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CA2659012A1 (en) * | 2006-07-26 | 2008-01-31 | Diamedica Inc. | Methods of diagnosis and treatment for metabolic disorders |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
US20100136561A1 (en) * | 2008-05-16 | 2010-06-03 | Interleukin Genetics, Inc. | Genetic Markers for Weight Management and Methods of Use Thereof |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101189639B1 (ko) * | 2008-12-15 | 2012-10-12 | 씨제이제일제당 (주) | 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법 |
WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
EP3797591A1 (en) | 2009-04-29 | 2021-03-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
CN101810628B (zh) * | 2010-04-13 | 2012-05-23 | 北京四环科宝制药有限公司 | 二甲双胍格列吡嗪片及其制备方法 |
EA023925B1 (ru) | 2010-04-27 | 2016-07-29 | Зилэнд Фарма А/С | Пептидные конъюгаты агонистов рецептора glp-1 и их применение |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
EA022365B1 (ru) | 2010-05-11 | 2015-12-30 | Янссен Фармацевтика Нв | Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012090225A2 (en) * | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
WO2012094636A2 (en) | 2011-01-07 | 2012-07-12 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
JP6359972B2 (ja) | 2011-11-03 | 2018-07-18 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体アゴニストペプチドガストリンコンジュゲート |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
ES2832773T3 (es) | 2012-01-06 | 2021-06-11 | Anji Pharma Us Llc | Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos |
AU2013207329B2 (en) | 2012-01-06 | 2017-10-26 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
WO2013115742A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Pharmaceutical composition comprising alpha-glucosidase inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
ES2625548T3 (es) | 2012-06-04 | 2017-07-19 | DiaMedica Therapeutics Inc. | Isoformas de glicosilación de la calicreína-1 tisular humana |
BR112015001451B1 (pt) | 2012-07-23 | 2022-03-29 | Zealand Pharma A/S | Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
KR101336499B1 (ko) * | 2013-03-06 | 2013-12-03 | 씨제이제일제당 (주) | 당뇨병의 예방 또는 치료용 복합 조성물 |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MY176022A (en) | 2013-10-17 | 2020-07-21 | Boehringer Ingelheim Int | Acylated glucagon analogues |
AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
EP3065767B1 (en) | 2013-11-06 | 2020-12-30 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
CA2980978A1 (en) | 2015-04-16 | 2016-10-20 | Zealand Pharma A/S | Acylated glucagon analogue |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
DK3551651T3 (da) | 2016-12-09 | 2024-05-13 | Zealand Pharma As | Acylerede glp-1/glp-2-dobbeltagonister |
WO2018165551A1 (en) | 2017-03-09 | 2018-09-13 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
WO2020068827A1 (en) * | 2018-09-24 | 2020-04-02 | Pendulum Therapeutics, Inc. | Microbial compositions and methods of use |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
CN113648318B (zh) * | 2020-05-12 | 2023-08-25 | 中国科学院上海营养与健康研究所 | 增强细胞产热和治疗疾病的应用 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029314A1 (en) * | 1997-12-08 | 1999-06-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
DE2348334C2 (de) | 1973-09-26 | 1982-11-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs |
US4060634A (en) | 1973-09-26 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Rapidly resorbable glibenclamide |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
EP0062704A1 (de) | 1980-12-03 | 1982-10-20 | Hoechst Aktiengesellschaft | Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4916163A (en) | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
PT998271E (pt) * | 1997-06-06 | 2005-10-31 | Depomed Inc | Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis |
ZA985126B (en) | 1997-06-13 | 1998-12-14 | Novo Nordisk As | Novel niddm regimen |
ATE355840T1 (de) | 1997-06-18 | 2007-03-15 | Smithkline Beecham Plc | Behandlung der diabetes mit thiazolidindione und metformin |
GB9715306D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
WO1999020275A1 (en) | 1997-10-17 | 1999-04-29 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
FR2774591B1 (fr) | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
FI111167B (fi) * | 1998-02-24 | 2003-06-13 | Kemira Chemicals Oy | Menetelmä lietteen säilyvyyden parantamiseksi |
WO1999043705A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
PT974356E (pt) | 1998-07-15 | 2004-02-27 | Merck Sante Sas | Comprimidos compreendendo uma combinacao de metformina e de glibenclamida |
HUP0104108A2 (hu) | 1998-09-17 | 2002-03-28 | Bristol-Myers Squibb Company | Eljárás diabétesz kezelésére egy aP2 inhibitor vagy kombinációja alkalmazásával |
AR028299A1 (es) | 1999-09-17 | 2003-05-07 | Novartis Ag | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. |
EP2620443A1 (en) | 2012-01-25 | 2013-07-31 | Galecto Biotech AB | Novel galactoside inhibitors of galectins |
-
1999
- 1999-11-03 US US09/432,465 patent/US6586438B2/en not_active Expired - Lifetime
- 1999-12-14 US US09/460,920 patent/US7598262B2/en not_active Expired - Lifetime
-
2000
- 2000-10-13 CA CA002389931A patent/CA2389931A1/en not_active Abandoned
- 2000-10-13 AU AU80229/00A patent/AU781781B2/en not_active Ceased
- 2000-10-13 UA UA2002054480A patent/UA76706C2/uk unknown
- 2000-10-13 CZ CZ20021546A patent/CZ304090B6/cs not_active IP Right Cessation
- 2000-10-13 BR BR0015295-1A patent/BR0015295A/pt not_active Application Discontinuation
- 2000-10-13 CZ CZ20021547A patent/CZ20021547A3/cs unknown
- 2000-10-13 JP JP2001534363A patent/JP2003529551A/ja active Pending
- 2000-10-13 ES ES00972122T patent/ES2302702T3/es not_active Expired - Lifetime
- 2000-10-13 NZ NZ552074A patent/NZ552074A/en not_active IP Right Cessation
- 2000-10-13 WO PCT/US2000/028467 patent/WO2001032158A2/en active IP Right Grant
- 2000-10-13 DE DE60038455T patent/DE60038455T2/de not_active Expired - Lifetime
- 2000-10-13 CN CNB008180288A patent/CN100386114C/zh not_active Expired - Lifetime
- 2000-10-13 EP EP00970913A patent/EP1253944A2/en not_active Withdrawn
- 2000-10-13 RO ROA200200560A patent/RO123109B1/ro unknown
- 2000-10-13 PL PL00366112A patent/PL366112A1/xx not_active Application Discontinuation
- 2000-10-13 EE EEP200200241A patent/EE05210B1/xx not_active IP Right Cessation
- 2000-10-13 CN CN2011101796999A patent/CN102283853A/zh active Pending
- 2000-10-13 UA UA2002054481A patent/UA75583C2/uk unknown
- 2000-10-13 SK SK499-2002A patent/SK4992002A3/sk not_active Application Discontinuation
- 2000-10-13 IL IL14913800A patent/IL149138A0/xx active IP Right Grant
- 2000-10-13 KR KR1020027005673A patent/KR100769786B1/ko active IP Right Grant
- 2000-10-13 KR KR1020027005677A patent/KR20020050253A/ko not_active Application Discontinuation
- 2000-10-13 CN CN2008100817553A patent/CN101273981B/zh not_active Expired - Lifetime
- 2000-10-13 HU HU0300642A patent/HUP0300642A3/hu unknown
- 2000-10-13 GE GE4802A patent/GEP20053539B/en unknown
- 2000-10-13 RU RU2002113764/15A patent/RU2276604C2/ru not_active IP Right Cessation
- 2000-10-13 GE GE4798A patent/GEP20053538B/en unknown
- 2000-10-13 MX MXPA02004290A patent/MXPA02004290A/es not_active Application Discontinuation
- 2000-10-24 MY MYPI20004995A patent/MY136636A/en unknown
- 2000-10-24 MY MYPI20004996A patent/MY125118A/en unknown
- 2000-10-27 TW TW089122629A patent/TWI241185B/zh not_active IP Right Cessation
- 2000-10-27 TN TNTNSN00207A patent/TNSN00207A1/en unknown
- 2000-10-27 TN TNTNSN00206A patent/TNSN00206A1/en unknown
- 2000-11-02 UY UY26425A patent/UY26425A1/es unknown
- 2000-11-03 AR ARP000105804A patent/AR026355A1/es unknown
-
2002
- 2002-04-15 IL IL149138A patent/IL149138A/en not_active IP Right Cessation
- 2002-04-15 IL IL149139A patent/IL149139A/en active IP Right Grant
- 2002-04-26 ZA ZA200203367A patent/ZA200203367B/xx unknown
- 2002-04-26 ZA ZA200203368A patent/ZA200203368B/xx unknown
- 2002-05-02 NO NO20022086A patent/NO20022086L/no unknown
- 2002-05-22 BG BG106732A patent/BG106732A/bg unknown
- 2002-05-22 BG BG106733A patent/BG65850B1/bg unknown
- 2002-05-24 LT LT2002062A patent/LT5025B/lt not_active IP Right Cessation
- 2002-06-03 LV LVP-02-93A patent/LV12907B/en unknown
- 2002-09-30 HK HK02107208.1A patent/HK1045655A1/zh unknown
-
2012
- 2012-09-25 JP JP2012211400A patent/JP2013028631A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029314A1 (en) * | 1997-12-08 | 1999-06-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100769786B1 (ko) | 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 | |
KR20070089259A (ko) | 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물 | |
US7507768B2 (en) | Antidiabetic formulation and method | |
JP2003519621A5 (ko) | ||
AU8022900B2 (ko) | ||
AU2002357095B2 (en) | Antidiabetic formulation and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20120924 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130926 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140923 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181004 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191001 Year of fee payment: 13 |